Mayukh Sukhatme Sells 339,441 Shares of Roivant Sciences (NASDAQ:ROIV) Stock

Roivant Sciences Ltd. (NASDAQ:ROIV) insider Mayukh Sukhatme sold 339,441 shares of the business’s stock in a transaction dated Monday, February 9th. The shares were sold at an average price of $26.47, for a total value of $8,985,003.27. Following the completion of the sale, the insider directly owned 19,148,664 shares of the company’s stock, valued at $506,865,136.08. The trade was a 1.74% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Mayukh Sukhatme also recently made the following trade(s):

• On Monday, December 29th, Mayukh Sukhatme sold 311,873 shares of Roivant Sciences stock. The stock was sold at an average price of $21.74, for a total value of $6,780,119.02.
• On Wednesday, December 31st, Mayukh Sukhatme sold 1,018,995 shares of Roivant Sciences stock. The shares were sold at an average price of $21.71, for a total value of $22,122,381.45.
• On Wednesday, December 17th, Mayukh Sukhatme sold 26,831 shares of Roivant Sciences stock. The shares were sold at an average price of $23.09, for a total value of $619,527.79.

Roivant Sciences Trading Down 2.0%

Shares of ROIV traded down $0.55 during trading hours on Wednesday, reaching $26.80. The stock had a trading volume of 5,380,288 shares, compared to its average volume of 7,009,321. Roivant Sciences Ltd. has a 12 month low of $8.73 and a 12 month high of $27.94. The firm has a 50-day simple moving average of $22.36 and a 200 day simple moving average of $18.08. The company has a market capitalization of $18.64 billion, a price-to-earnings ratio of -22.91 and a beta of 1.22.

Institutional Trading of Roivant Sciences

Hedge funds have recently made changes to their positions in the company. Penn Davis Mcfarland Inc. boosted its position in Roivant Sciences by 10.1% during the third quarter. Penn Davis Mcfarland Inc. now owns 1,862,088 shares of the company’s stock worth $28,173,000 after purchasing an additional 170,456 shares during the period. Valeo Financial Advisors LLC bought a new stake in shares of Roivant Sciences in the second quarter valued at approximately $1,145,000. IFG Advisory LLC bought a new stake in shares of Roivant Sciences in the second quarter valued at approximately $255,000. Y Intercept Hong Kong Ltd purchased a new stake in shares of Roivant Sciences during the 2nd quarter valued at approximately $3,064,000. Finally, iSAM Funds UK Ltd boosted its holdings in Roivant Sciences by 244.8% in the 2nd quarter. iSAM Funds UK Ltd now owns 137,468 shares of the company’s stock worth $1,549,000 after buying an additional 97,600 shares during the period. 64.76% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several brokerages have recently commented on ROIV. Jefferies Financial Group reissued a “buy” rating and issued a $30.00 price objective on shares of Roivant Sciences in a research note on Monday. The Goldman Sachs Group raised their price objective on Roivant Sciences from $24.00 to $33.00 and gave the company a “buy” rating in a research note on Monday, December 15th. Guggenheim upped their target price on shares of Roivant Sciences from $28.00 to $30.00 and gave the stock a “buy” rating in a research note on Monday. Leerink Partners raised their price target on shares of Roivant Sciences from $29.00 to $32.00 and gave the company an “outperform” rating in a research report on Monday, December 15th. Finally, Weiss Ratings downgraded shares of Roivant Sciences from a “hold (c-)” rating to a “sell (d)” rating in a research report on Monday. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $28.69.

Roivant Sciences Company Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.